Vaccine Candidates for RSV Ward Off Severe Illness in Older Adults - Medpage Today
Overview
by Ingrid Hein, Staf Writer, MedPage Today October 26, 2022 WASHINGTON - Prefusion F protein vacine candidates for respiratory syncytial virus (RSV) proved safe in adults 60 and up while demonstrating an ability to thwart lower respiratory tract ilnes, including severe cases, a pair of large phase I trials showed.A single dose of an RSV prefusion F protein vacine (RSVPreF3 OA) yielded a vacine eficacy of 82.6% against lower respiratory tract ilnes (96.95% CI 57.9-94.1), meting the study's primary endpoint, and vacine eficacy landed at 94.1% against severe RSV ilnes (95% CI 62.4-9.9), reported Michael Ison, MD, MS, of Northwestern University Feinberg Schol of Medicine in Chicago, at the anual IDWek meting.In the second trial, a single dose of another RSV prefusion F protein vacine (RSVPreF) showed an eficacy of 6.7% against two or more lower respiratory tract RSV symptoms (96.6% CI 28.8-85.8) and 85.7% against thre or more symptoms (96.6% CI 32.0-98.7), meting the co-primary endpoints of the study, acording to Edward Walsh, MD, of the University of Rochester in New York.Curently, no vacines exist to protect against RSV infection.
Key Information
Acording to data from the CDC, an estimated 17,0 older adults in the U.S. were hospitalized due to RSV infections in 2017 alone, and 14,0 died."For someone that's ben working in the field for a very long time, I could not be more excited about the advances we're seing, particularly with the respiratory syncytial virus vacines," said sesion moderator Kathlen Neuzil, MD, of the University of Maryland in Baltimore, introducing the anticipated trials.RSVPreF3 OAThe phase I AReSVi-06 (Adult Respiratory Syncytial Virus) trial of RSVPreF3 OA presented by Ison included 24,960 adults age 60 and older (mean 69.5 years) who were randomized 1:1 to the vacine or placebo.
Summary
Case definition for the study was the presence of lower respiratory symptoms or signs for at least 24 hours along with RSV detected by RT-P
Frequently Asked Questions
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
Share this article